These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 6804884)

  • 1. Dopamine receptors in a rat model of minimal brain dysfunction.
    Eisenberg J; Brecher-Fride E; Weizman R; Ebstein RP; Belmaker RH
    Neuropsychobiology; 1982; 8(3):151-5. PubMed ID: 6804884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin effect on learning in 6-hydroxydopamine-pretreated rats: correlation with caudate vasopressin levels.
    Hamburger-Bar R; Ebstein RP; Belmaker RH
    Biol Psychiatry; 1984 May; 19(5):735-43. PubMed ID: 6428473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian steroids modulate the release of dopamine into hypophysial portal blood and the density of anterior pituitary [3H]spiperone-binding sites in ovariectomized rats.
    Pilotte NS; Burt DR; Barraclough CA
    Endocrinology; 1984 Jun; 114(6):2306-11. PubMed ID: 6723585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal 6-OHDA lesions differentially affect striatal D1 and D2 receptors.
    Neal BS; Joyce JN
    Synapse; 1992 May; 11(1):35-46. PubMed ID: 1351321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine.
    Duncan GE; Criswell HE; McCown TJ; Paul IA; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1027-34. PubMed ID: 3121842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder.
    Volkow ND; Wang GJ; Newcorn J; Telang F; Solanto MV; Fowler JS; Logan J; Ma Y; Schulz K; Pradhan K; Wong C; Swanson JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):932-40. PubMed ID: 17679638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoradiographic localization of dopamine DA-2 receptor sites in rat mesenteric vascular tree.
    Ricci A; Amenta F
    J Pharmacol Exp Ther; 1990 Aug; 254(2):750-5. PubMed ID: 2143538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: a preliminary report.
    Wong DF; Wagner HN; Pearlson G; Dannals RF; Links JM; Ravert HT; Wilson AA; Suneja S; Bjorvvinssen E; Kuhar MJ
    Psychopharmacol Bull; 1985; 21(3):595-8. PubMed ID: 4034877
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopamine receptors, neuroleptics, and schizophrenia.
    Snyder SH
    Am J Psychiatry; 1981 Apr; 138(4):460-4. PubMed ID: 6111227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the young dopamine-lesioned rat as an animal model for minimal brain dysfunction (MBD).
    Thieme RE; Dijkstra H; Stoof JC
    Psychopharmacology (Berl); 1980 Feb; 67(2):165-9. PubMed ID: 6768092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine (3,4-dihydroxyphenethylamine) receptor binding in subcellular fractions from bovine caudate [proceedings].
    Withy RM; Mayer RJ; Strange PG
    Biochem Soc Trans; 1979 Apr; 7(2):414-6. PubMed ID: 428670
    [No Abstract]   [Full Text] [Related]  

  • 14. Noradrenaline and dopamine interaction in rat brain during development.
    Ponzio F; Hallman H; Jonsson G
    Med Biol; 1981 Jun; 59(3):161-9. PubMed ID: 6796787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].
    Martin GE; Williams M; Pettibone DJ; Yarbrough GG; Clineschmidt BV; Jones JH
    J Pharmacol Exp Ther; 1984 Sep; 230(3):569-76. PubMed ID: 6433000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction.
    Shaywitz BA; Yager RD; Klopper JH
    Science; 1976 Jan; 191(4224):305-8. PubMed ID: 942800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prepuberal intranasal dopamine treatment in an animal model of ADHD ameliorates deficient spatial attention, working memory, amino acid transmitters and synaptic markers in prefrontal cortex, ventral and dorsal striatum.
    Ruocco LA; Treno C; Gironi Carnevale UA; Arra C; Mattern C; Huston JP; de Souza Silva MA; Nikolaus S; Scorziello A; Nieddu M; Boatto G; Illiano P; Pagano C; Tino A; Sadile AG
    Amino Acids; 2014 Sep; 46(9):2105-22. PubMed ID: 24862315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substantia nigra 6-hydroxydopamine lesions alter dopaminergic synaptic markers in the nucleus basalis magnocellularis and striatum of rats.
    Geula C; Slevin JT
    Synapse; 1989; 4(3):248-53. PubMed ID: 2532792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of brain neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Am J Psychiatry; 1980 Feb; 137(2):191-7. PubMed ID: 6101525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.